Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
Orchard Therapeutics Celebrates Addition of Metachromatic Leukodystrophy to the U.S. Recommended Uniform Screening Panel
Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
Orchard Therapeutics Announces Reimbursement Agreement in Spain
Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD
Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™
Orchard Therapeutics Announces Multiple Data Presentations and Publications
Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian Countries
Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Portfolio at SSIEM 2024
Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day
Sorrento Therapeutics (OTCMKTS:SRNEQ) and bluebird bio (NASDAQ:BLUE) Financial Comparison
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
US approves first gene therapy for rare genetic disease
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin
Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains?
Why Orchard Therapeutics Stock Is Soaring Today
Orchard Therapeutics is being bought at a massive premium
ORTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Orchard Therapeutics plc Is Fair to Shareholders
Orchard Therapeutics shares double following Japanese bid approach
Why Is Orchard Therapeutics (ORTX) Stock Up 98% Today?
Orchard Therapeutics shares nearly double on buyout deal
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln
Kyowa Kirin to Acquire Orchard Therapeutics
Orchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock?
Orchard's (ORTX) Rare Neuro Drug Gets FDA Priority Tag, Stock Up
Orchard Therapeutics: A Reassessment
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023
Wall Street Analysts Think Orchard Therapeutics PLC Sponsored ADR (ORTX) Could Surge 365.03%: Read This Before Placing a Bet
Orchard Therapeutics plc (ORTX) Q2 2023 Earnings Call Transcript
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel
Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results
Orchard Therapeutics to Present at Stifel's Genetic Medicines Day
Orchard Therapeutics: MLD Opportunity Could Be Larger Than Initial Estimates